FDA approves Dova’s Doptelet for thrombocytopenia in adults with CLD
The approval for the thrombopoietin (TPO) receptor agonist is for adult patients who are scheduled to go through a medical or dental procedure. The regulator said Doptelet is the
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.